Skip to content
Back to meeting Original
ESMO - Eur. Oncology· @myESMO · X·· 3 hours agoScore70

FOURLIGHT-1

Body

#ESMO26: Next-generation CDK4 inhibitor atirmociclib in combination with fulvestrant extends PFS by 3 months in endocrine-resistant #AdvancedBreastCancer in the phase II FOURLIGHT-1 #ClinicalTrial

🔗 https://ow.ly/99yu5100p14

#InsightsbyESMO #BreastCancer

138 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage

Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)

https://esmocongress.esmo.org

Source: ESMO - Eur. Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.